OGN vs. ROIV, BBIO, MRNA, QGEN, ELAN, VRNA, RVMD, MRUS, GRFS, and RYTM
Should you be buying Organon & Co. stock or one of its competitors? The main competitors of Organon & Co. include Roivant Sciences (ROIV), BridgeBio Pharma (BBIO), Moderna (MRNA), Qiagen (QGEN), Elanco Animal Health (ELAN), Verona Pharma PLC American Depositary Share (VRNA), Revolution Medicines (RVMD), Merus (MRUS), Grifols (GRFS), and Rhythm Pharmaceuticals (RYTM). These companies are all part of the "pharmaceutical products" industry.
Organon & Co. vs. Its Competitors
Roivant Sciences (NASDAQ:ROIV) and Organon & Co. (NYSE:OGN) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, analyst recommendations and institutional ownership.
Organon & Co. has a net margin of 11.15% compared to Roivant Sciences' net margin of -2,111.79%. Organon & Co.'s return on equity of 163.88% beat Roivant Sciences' return on equity.
Roivant Sciences has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500. Comparatively, Organon & Co. has a beta of 0.63, meaning that its stock price is 37% less volatile than the S&P 500.
64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 77.4% of Organon & Co. shares are held by institutional investors. 10.8% of Roivant Sciences shares are held by insiders. Comparatively, 1.4% of Organon & Co. shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
In the previous week, Organon & Co. had 2 more articles in the media than Roivant Sciences. MarketBeat recorded 6 mentions for Organon & Co. and 4 mentions for Roivant Sciences. Organon & Co.'s average media sentiment score of 1.52 beat Roivant Sciences' score of 0.94 indicating that Organon & Co. is being referred to more favorably in the news media.
Roivant Sciences currently has a consensus price target of $19.94, indicating a potential upside of 22.05%. Organon & Co. has a consensus price target of $17.33, indicating a potential upside of 59.09%. Given Organon & Co.'s higher possible upside, analysts plainly believe Organon & Co. is more favorable than Roivant Sciences.
Organon & Co. has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.
Summary
Organon & Co. beats Roivant Sciences on 11 of the 16 factors compared between the two stocks.
Get Organon & Co. News Delivered to You Automatically
Sign up to receive the latest news and ratings for OGN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding OGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Organon & Co. Competitors List
Related Companies and Tools
This page (NYSE:OGN) was last updated on 10/6/2025 by MarketBeat.com Staff
